MMP14 and colitis: Thus, endothelium‐specific MT1‐MMP deletion improves 1% DSS‐induced colitis progression primarily through an early impact on IA events at 3 days rather than on vascular perfusion, leukocyte traffic, and tissue alterations modulated at 7 days.